177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mandel Philipp, Groener Daniel, Follacchio Giulia, Ürün Yüksel, Bourlon Maria T, Sabet Amir, Grünwald Frank, Tural Deniz, Büttner Thomas, Kopp Ray Manneh, Taha Tarek, Chun Felix Kh, Facchini Gaetano, Myint Zin W, Seront Emmanuel, Conteduca Vincenza, Quiroga María Natalia Gandur, Aurilio Gaetano, Palacios Georgia Anguera, Bögemann Martin, Roviello Giandomenico, Matrana Marc R, Sammarco Enrico, Laguado Martin Ignacio Zapata, Galli Luca, Ansari Jawaher, Danielli Linda, Molina-Cerrillo Javier, Rescigno Pasquale, Yazgan Sati Coskun, Bastos Diogo Assed, Jazieh Abdul Rahman, Monteiro Fernando Sabino Marques, Soares Andrey, Massari Francesco, Wenzel Mike, Capoccetti Francesca, Santoni Matteo
Аннотация
METHODS: Real-word data from the ARON-3 collaboration in progressive mCRPC patients treated with 177Lu-PSMA vs. cabazitaxel were collected. A retrospective analysis was performed, including overall survival (OS), progression free survival (PFS), time to treatment failure (TTF) and PSA50/90 rates.
RESULTS: Data from 285 (50.1 %) patients receiving 177Lu-PSMA vs. 283 (49.9 %) cabazitaxel after one or two lines of ARPI and Docetaxel were analyzed. PSA50 and PSA90 rates were higher, and TTF and OS were significantly longer in 177Lu-PSMA patients, even after multivariable adjustment (p ≤ 0.01). This effect held true for most subgroups such as age < 70 and ≥ 70 years, ECOG 0-1, distant lymph nodes and one vs. two lines of prior ARPI. Incidence of grade 3-4 adverse events were comparable between both treatments (37 % vs. 43 % for 177Lu-PSMA vs. cabazitaxel cohort p = 0.5) but differed according to the type of adverse events. Sensitivity analyses with cross-over adjustment showed similar effects.
CONCLUSIONS: Analyzing the currently largest real-world cohort comparing 177Lu-PSMA vs. cabazitaxel, we provided robust information of 177Lu-PSMA being at least equally effective or possibly even superior to cabazitaxel regarding cancer-control outcomes with reasonable side effects.